Last updated: October 25, 2026

Application No. 17/820,232

CELL-TO-CELL DELIVERY OF RNA CIRCUITS

Final Rejection

Filed

Aug 16, 2022

Priority

Aug 17, 2021 — provisional 63/234,085 +1 more

Examiner

PENNINGTON, KATIE LEIGH

Art Unit

1634

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

California Institute of Technology

OA Round

2 (Final)

Interview Optional

— +58.8% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 32% grant rate with +58.8% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 66 resolved cases, 2023–2026

Examiner Intelligence

PENNINGTON, KATIE LEIGH View full profile →

Grants only 32% of cases

Career Allowance Rate

21 granted / 66 resolved

-28.2% vs TC avg

Strong +59% interview lift

Without

With

+58.8%

Interview Lift

resolved cases with interview

Typical timeline

4y 1m

Avg Prosecution

51 currently pending

Career history

135

Total Applications

across all art units

Statute-Specific Performance

§101

3.9%

-36.1% vs TC avg

§103

41.1%

+1.1% vs TC avg

§102

13.5%

-26.5% vs TC avg

§112

29.9%

-10.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 66 resolved cases

Prosecution Timeline

Aug 16, 2022

Application Filed

Nov 03, 2025

Interview Requested

Nov 12, 2025

Examiner Interview Summary

Nov 12, 2025

Applicant Interview (Telephonic)

Feb 25, 2026

Non-Final Rejection mailed

May 26, 2026

Response Filed

Aug 20, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/162,356

Patent 12735459

MODIFIED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR OCULAR GENE THERAPY AND METHODS OF USE THEREOF

5y 7m to grant Granted Sep 15, 2026

17/760,715

Patent 12714755

EFFECTIVE DOSAGES OF AN ADENOVIRAL-BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS IN HUMANS, AND COMPOSITIONS COMPRISING THE SAME

4y 5m to grant Granted Aug 25, 2026

17/388,906

Patent 12703695

KU INHIBITORS AND THEIR USE

5y 0m to grant Granted Aug 11, 2026

17/267,247

Patent 12612644

SCALABLE METHOD FOR RECOMBINANT AAV PRODUCTION

5y 2m to grant Granted Apr 28, 2026

17/419,236

Patent 12583896

CAGED-DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME

4y 9m to grant Granted Mar 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

32%

Grant Probability

91%

With Interview (+58.8%)

4y 1m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 66 resolved cases by this examiner. Grant probability derived from career allowance rate.